Ensuring Data Integrity and 21 CFR Part 11 Compliance in NGS Workflows

Advancing NGS Compliance: How Avance Aligns Data Integrity with 21 CFR Part 11

As next-generation and third-generation sequencing technologies take on greater roles in GMP lot release, GLP studies, and clinical trials, the stakes for data integrity and regulatory compliance have never been higher. What was once limited to research now operates firmly within the boundaries of FDA oversight—and the expectations have evolved accordingly.

At Avance, we’ve developed a comprehensive framework for ensuring sequencing workflows meet the rigorous standards of 21 CFR Part 11. It’s not just about collecting data—it’s about generating results that are reliable, auditable, and defensible at every step.

Many NGS platforms, while powerful, weren’t built with compliance in mind. Features like immutable data storage, controlled access, and full audit trails are often missing or require complex workarounds. And when you add the variability of custom bioinformatics pipelines and open-source tools, maintaining traceability becomes even more challenging.

Avance addresses these issues with a purpose-built approach tailored to regulated environments. Our systems combine secure data acquisition, validated bioinformatics pipelines, audit-ready infrastructure, and a fully integrated LIMS environment. Every action, from data generation to re-analysis, is logged, verified, and protected.

We’ve also implemented a multi-layered backup and validation strategy to ensure data authenticity and reproducibility across every run—key for organizations navigating FDA submissions or scaling compliant sequencing operations.

Want a deeper look into how we built this framework—and how it’s helping clients stay ahead of regulatory demands?

Download our latest technote to explore the core principles behind our compliance-driven workflows and see what sets Avance apart in the NGS space.